Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

Background The third generation Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor(TKI) osimertinibhas been initially approved for T790Mpositive Non-Small Cell Lung Cancer (NSCLC) and more recently for first-line treatment of EGFR-mutant T790Mnegative NSCLC patients. Similarly to previous generation TKIs, despite the high response rate, disease progression eventually occurs and current clinical research is focused on novel strategies to delay the emergence of osimertinibresistance. In this study we investigated the combination of osimertinibwith pemetrexedor cisplatin in EGFR-mutated NSCLC cell lines and xenografts.